Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT

G van Gorkom, M van Gelder, DJ Eikema, HJ Blok, MT van Lint, Y Koc, F Ciceri, D Beelen, P Chevallier, D Selleslag, D Blaise, Roberto Foá, P Corradini, L Castagna, C. Moreno, Carlos Solano, LP Müller, J Tischer, I Hilgendorf, M HallekJ Bittenbring, M Theobald, J Schetelig, N Kröger, on behalf of the CLL subcommittee & Chronic Malignancies Working Party of the EBMT

Research output: Contribution to journalArticle

Abstract

Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic lymphocytic leukemia (CLL). Recently, haploidentical HCT is gaining interest because of better outcomes with post-transplantation cyclophosphamide (PTCY). We analyzed patients with CLL who received an allogeneic HCT with a haploidentical donor and whose data were available in the EBMT registry. In total 117 patients (74% males) were included; 38% received PTCY as GVHD prophylaxis. For the whole study cohort OS at 2 and 5 yrs was 48 and 38%, respectively. PFS at 2 and 5 yrs was 38 and 31%, respectively. Cumulative incidence (CI) of NRM in the whole group at 2 and 5 years were 40 and 44%, respectively. CI of relapse at 2 and 5 yrs were 22 and 26%, respectively. All outcomes were not statistically different in patients who received PTCY compared to other types of GVHD prophylaxis. In conclusion, results of haploidentical HCT in CLL seem almost identical to those with HLA-matched donors. Thereby, haploidentical HCT is an appropriate alternative in high risk CLL patients with a transplant indication but no available HLA-matched donor. Despite the use of PTCY, the CI of relapse seems not higher than observed after HLA-matched HCT.
Original languageEnglish
Pages (from-to)255-263
Number of pages9
JournalBone Marrow Transplantation
Volume53
DOIs
Publication statusPublished - 2018

Fingerprint

Hematopoietic Stem Cell Transplantation
Stem Cell Transplantation
B-Cell Chronic Lymphocytic Leukemia
Retrospective Studies
Cyclophosphamide
Transplantation
Neoplasms
Tissue Donors
Incidence
Recurrence
Registries
Cohort Studies
Transplants

Cite this

Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. / van Gorkom, G; van Gelder, M; Eikema, DJ; Blok, HJ; van Lint, MT; Koc, Y; Ciceri, F; Beelen, D; Chevallier, P; Selleslag, D; Blaise, D; Foá, Roberto; Corradini, P; Castagna, L; Moreno, C.; Solano, Carlos; Müller, LP; Tischer, J; Hilgendorf, I; Hallek, M; Bittenbring, J; Theobald, M; Schetelig, J; Kröger, N; EBMT, on behalf of the CLL subcommittee & Chronic Malignancies Working Party of the.

In: Bone Marrow Transplantation, Vol. 53, 2018, p. 255-263.

Research output: Contribution to journalArticle

van Gorkom, G, van Gelder, M, Eikema, DJ, Blok, HJ, van Lint, MT, Koc, Y, Ciceri, F, Beelen, D, Chevallier, P, Selleslag, D, Blaise, D, Foá, R, Corradini, P, Castagna, L, Moreno, C, Solano, C, Müller, LP, Tischer, J, Hilgendorf, I, Hallek, M, Bittenbring, J, Theobald, M, Schetelig, J, Kröger, N & EBMT, OBOTCLLSCMWPOT 2018, 'Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT', Bone Marrow Transplantation, vol. 53, pp. 255-263. https://doi.org/10.1038/s41409-017-0023-2
van Gorkom, G ; van Gelder, M ; Eikema, DJ ; Blok, HJ ; van Lint, MT ; Koc, Y ; Ciceri, F ; Beelen, D ; Chevallier, P ; Selleslag, D ; Blaise, D ; Foá, Roberto ; Corradini, P ; Castagna, L ; Moreno, C. ; Solano, Carlos ; Müller, LP ; Tischer, J ; Hilgendorf, I ; Hallek, M ; Bittenbring, J ; Theobald, M ; Schetelig, J ; Kröger, N ; EBMT, on behalf of the CLL subcommittee & Chronic Malignancies Working Party of the. / Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. In: Bone Marrow Transplantation. 2018 ; Vol. 53. pp. 255-263.
@article{f3ea43a3c9314d12be35ae9b97d33685,
title = "Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT",
abstract = "Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic lymphocytic leukemia (CLL). Recently, haploidentical HCT is gaining interest because of better outcomes with post-transplantation cyclophosphamide (PTCY). We analyzed patients with CLL who received an allogeneic HCT with a haploidentical donor and whose data were available in the EBMT registry. In total 117 patients (74{\%} males) were included; 38{\%} received PTCY as GVHD prophylaxis. For the whole study cohort OS at 2 and 5{\^a}€‰yrs was 48 and 38{\%}, respectively. PFS at 2 and 5 yrs was 38 and 31{\%}, respectively. Cumulative incidence (CI) of NRM in the whole group at 2 and 5 years were 40 and 44{\%}, respectively. CI of relapse at 2 and 5 yrs were 22 and 26{\%}, respectively. All outcomes were not statistically different in patients who received PTCY compared to other types of GVHD prophylaxis. In conclusion, results of haploidentical HCT in CLL seem almost identical to those with HLA-matched donors. Thereby, haploidentical HCT is an appropriate alternative in high risk CLL patients with a transplant indication but no available HLA-matched donor. Despite the use of PTCY, the CI of relapse seems not higher than observed after HLA-matched HCT.",
author = "{van Gorkom}, G and {van Gelder}, M and DJ Eikema and HJ Blok and {van Lint}, MT and Y Koc and F Ciceri and D Beelen and P Chevallier and D Selleslag and D Blaise and Roberto Fo{\'a} and P Corradini and L Castagna and C. Moreno and Carlos Solano and LP M{\"u}ller and J Tischer and I Hilgendorf and M Hallek and J Bittenbring and M Theobald and J Schetelig and N Kr{\"o}ger and EBMT, {on behalf of the CLL subcommittee & Chronic Malignancies Working Party of the}",
year = "2018",
doi = "10.1038/s41409-017-0023-2",
language = "English",
volume = "53",
pages = "255--263",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT

AU - van Gorkom, G

AU - van Gelder, M

AU - Eikema, DJ

AU - Blok, HJ

AU - van Lint, MT

AU - Koc, Y

AU - Ciceri, F

AU - Beelen, D

AU - Chevallier, P

AU - Selleslag, D

AU - Blaise, D

AU - Foá, Roberto

AU - Corradini, P

AU - Castagna, L

AU - Moreno, C.

AU - Solano, Carlos

AU - Müller, LP

AU - Tischer, J

AU - Hilgendorf, I

AU - Hallek, M

AU - Bittenbring, J

AU - Theobald, M

AU - Schetelig, J

AU - Kröger, N

AU - EBMT, on behalf of the CLL subcommittee & Chronic Malignancies Working Party of the

PY - 2018

Y1 - 2018

N2 - Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic lymphocytic leukemia (CLL). Recently, haploidentical HCT is gaining interest because of better outcomes with post-transplantation cyclophosphamide (PTCY). We analyzed patients with CLL who received an allogeneic HCT with a haploidentical donor and whose data were available in the EBMT registry. In total 117 patients (74% males) were included; 38% received PTCY as GVHD prophylaxis. For the whole study cohort OS at 2 and 5 yrs was 48 and 38%, respectively. PFS at 2 and 5 yrs was 38 and 31%, respectively. Cumulative incidence (CI) of NRM in the whole group at 2 and 5 years were 40 and 44%, respectively. CI of relapse at 2 and 5 yrs were 22 and 26%, respectively. All outcomes were not statistically different in patients who received PTCY compared to other types of GVHD prophylaxis. In conclusion, results of haploidentical HCT in CLL seem almost identical to those with HLA-matched donors. Thereby, haploidentical HCT is an appropriate alternative in high risk CLL patients with a transplant indication but no available HLA-matched donor. Despite the use of PTCY, the CI of relapse seems not higher than observed after HLA-matched HCT.

AB - Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic lymphocytic leukemia (CLL). Recently, haploidentical HCT is gaining interest because of better outcomes with post-transplantation cyclophosphamide (PTCY). We analyzed patients with CLL who received an allogeneic HCT with a haploidentical donor and whose data were available in the EBMT registry. In total 117 patients (74% males) were included; 38% received PTCY as GVHD prophylaxis. For the whole study cohort OS at 2 and 5 yrs was 48 and 38%, respectively. PFS at 2 and 5 yrs was 38 and 31%, respectively. Cumulative incidence (CI) of NRM in the whole group at 2 and 5 years were 40 and 44%, respectively. CI of relapse at 2 and 5 yrs were 22 and 26%, respectively. All outcomes were not statistically different in patients who received PTCY compared to other types of GVHD prophylaxis. In conclusion, results of haploidentical HCT in CLL seem almost identical to those with HLA-matched donors. Thereby, haploidentical HCT is an appropriate alternative in high risk CLL patients with a transplant indication but no available HLA-matched donor. Despite the use of PTCY, the CI of relapse seems not higher than observed after HLA-matched HCT.

U2 - 10.1038/s41409-017-0023-2

DO - 10.1038/s41409-017-0023-2

M3 - Article

VL - 53

SP - 255

EP - 263

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

ER -